A
Amani Therapeutics
Safer combination therapies for serious neuropsychiatric disorders.
About Amani Therapeutics
Amani Therapeutics is a New York-based biotechnology company that launched in March 2026, focused on developing safer and more effective medicines for severe neuropsychiatric disorders. The company was established with the backing of RTW Investments, a global investment firm specializing in the biopharmaceutical and medical technology sectors. Upon its formation, Amani Therapeutics announced a $25 million Series A financing round.
The company's primary business revolves around its lead program, AM-01, a potential therapy for treatment-resistant schizophrenia. This condition represents a significant unmet need in the psychiatric market. Amani's core strategy involves improving upon existing effective treatments by mitigating their adverse side effects. The business model is centered on the clinical development and subsequent commercialization of its proprietary drug candidates. Amani generates value by acquiring and developing promising pharmaceutical assets.
AM-01 is a fixed-dose combination product that includes clozapine and a novel chemical entity (NCE) for which Amani has in-licensed worldwide rights from AstraZeneca. Clozapine is recognized as the most effective medication for treatment-resistant schizophrenia and for reducing suicide risk in patients with schizophrenia and schizoaffective disorder. However, its use is severely limited due to the risk of severe neutropenia, a dangerous drop in white blood cells, which requires patients to undergo frequent and burdensome blood monitoring. Amani's product, AM-01, aims to deliver clozapine's efficacy while addressing this major safety liability. The in-licensed NCE is Phase 3-ready, which may streamline the clinical development pathway for AM-01.
Amani Therapeutics is led by a team of experienced executives. Rob Swoboda serves as Chief Operating Officer, bringing operational and commercialization experience from roles at Karuna Therapeutics, bluebird bio, and Vertex Pharmaceuticals. Dr. Carla Canuso, the Chief Medical Officer, has over two decades of experience in neuropsychiatric clinical development at Johnson & Johnson, where she led the development team for intranasal esketamine.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $25M | $100M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Amani Therapeutics is 780 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Amani Therapeutics in the New York City ecosystem
The Amani Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amani Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amani Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










